Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Koshien-Kyubancho, Nishinomiya-shi, Hyogo, Japan.
Biochem Pharmacol. 2011 Apr 1;81(7):866-72. doi: 10.1016/j.bcp.2011.01.010. Epub 2011 Jan 27.
We previously demonstrated that prostaglandin (PG) E₂ stimulates adhesion of mastocytoma P-815 cells (P-815 cells) to the Arg-Gly-Asp (RGD)-enriched matrix via the PGE₂ receptor subtype EP4 [Hatae N, Kita A, Tanaka S, Sugimoto Y, Ichikawa A. Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E₂ receptor subtypes, EP3 and EP4. J Biol Chem 2003;278:17977-81]. Here we investigated the role of various integrin subtypes in the induction of adherent activity in PGE(2)-stimulated P-815 cells. FACS analysis showed that P-815 cells express high levels of integrin α4, α5, β1 and β2 subunits and moderate levels of integrin αIIb, αv, β3 and β7 subunits. When treated with PGE₂, the EP4 agonist ONO-AE1-329 or the cell permeable cAMP analogue, 8-Br-cAMP, P-815 cells showed markedly increased cell surface expression of integrin αIIb, αv and β3 subunits, and these expressions were significantly reduced by addition of the protein synthesis inhibitor cycloheximide. Along with increased cell surface expression, mRNA and protein levels of the integrin β3 subunit, but not of integrin αIIb and αv subunits, were simultaneously elevated. On the other hand, adhesion of P-815 cells in response to PGE₂ or 8-Br-cAMP was abolished by antibodies specific for integrin αv and β3 subunits, but not by antibodies for integrin α4, α5, β1, β2 and β7 subunits. Moreover, treatment with tirofiban, an integrin αIIbβ3 antagonist, or eptifibatide, an integrin αvβ3/αIIbβ3 antagonist resulted in a decrease in adhesion of P-815 cells in response to PGE₂ or 8-Br-cAMP. These results suggest that de novo synthesis of the integrin β3 subunit plays a pivotal role in PGE₂-induced adhesion of P-815 cells to the RGD-enriched matrix through EP4-mediated cAMP signaling.
我们之前已经证明前列腺素(PG)E2 通过 PGE2 受体亚型 EP4 刺激肥大细胞瘤 P-815 细胞(P-815 细胞)与富含 Arg-Gly-Asp(RGD)的基质黏附[Hatae N、Kita A、Tanaka S、Sugimoto Y、Ichikawa A. 两种前列腺素 E2 受体亚型 EP3 和 EP4 的协同作用诱导肥大细胞瘤 P-815 细胞的黏附活性。J Biol Chem 2003;278:17977-81]。在这里,我们研究了各种整合素亚型在 PGE(2)刺激的 P-815 细胞中诱导黏附活性中的作用。FACS 分析显示,P-815 细胞表达高水平的整合素 α4、α5、β1 和 β2 亚基,以及中等水平的整合素 αIIb、αv、β3 和 β7 亚基。当用 PGE2、EP4 激动剂 ONO-AE1-329 或细胞可渗透的 cAMP 类似物 8-Br-cAMP 处理时,P-815 细胞表面表达的整合素 αIIb、αv 和 β3 亚基显著增加,而加入蛋白质合成抑制剂环己酰亚胺则显著减少。随着细胞表面表达的增加,整合素 β3 亚基的 mRNA 和蛋白水平同时升高,但整合素 αIIb 和 αv 亚基的水平没有升高。另一方面,针对整合素 αv 和 β3 亚基的抗体可消除 P-815 细胞对 PGE2 或 8-Br-cAMP 的黏附反应,而针对整合素 α4、α5、β1、β2 和 β7 亚基的抗体则没有。此外,用整合素 αIIbβ3 拮抗剂替罗非班或整合素 αvβ3/αIIbβ3 拮抗剂依替巴肽治疗可导致 P-815 细胞对 PGE2 或 8-Br-cAMP 的黏附反应减少。这些结果表明,新合成的整合素 β3 亚基通过 EP4 介导的 cAMP 信号在 PGE2 诱导的 P-815 细胞与富含 RGD 的基质黏附中起关键作用。